Federated Hermes
TRDA icon

Federated Hermes’s Entrada Therapeutics TRDA Stock Holding History

Federated Hermes’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
+1,968
New +$18.9K ﹤0.01% 1809
2025
Q4 		– Sell
-2,018
Closed -$11.7K – 2204
2025
Q3 		$11.7K Sell
2,018
-94,668
-98% -$554K ﹤0.01% 1868
2025
Q2 		$650K Sell
96,686
-2,034
-2% -$16.4K ﹤0.01% 1263
2025
Q1 		$892K Sell
98,720
-1,094
-1% -$13.6K ﹤0.01% 1141
2024
Q4 		$1.73M Buy
99,814
+96,699
+3,104% +$1.75M ﹤0.01% 968
2024
Q3 		$49.8K Buy
3,115
+2,165
+228% +$34.1K ﹤0.01% 1664
2024
Q2 		$13.5K Buy
950
+62
+7% +$881 ﹤0.01% 1758
2024
Q1 		$12.6K Sell
888
-20
-2% -$283 ﹤0.01% 1759
2023
Q4 		$13.7K Buy
+908
New +$13.5K ﹤0.01% 1770

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Federated Hermes's TRDA Position: Q2 2026 in Review

Federated Hermes opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 1,968 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #1809 among its holdings. This is a return to the name: Federated Hermes previously reported a position in TRDA as recently as Q3 2025.

Federated Hermes first reported a position in TRDA in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.73M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Federated Hermes held 1,968 shares of Entrada Therapeutics worth $14.5K as of Q2 2026.
  • Entrada Therapeutics was a new Federated Hermes position in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1809 holding.
  • Federated Hermes first reported a position in Entrada Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Federated Hermes's Entrada Therapeutics position peaked at $1.73M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.